Products & Services · Additions
AstraZeneca milestone — Additions
Insmed AstraZeneca milestone — Additions decreased by 100.0% to $0.00 in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $11.25M to $0.00. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityVolatile
First reportedQ1 2025
Last reportedQ1 2026
How to read this metric
An increase signals successful progression of clinical or regulatory milestones, indicating positive momentum in the partnered pipeline.
Detailed definition
This represents the gross increase in the value of intangible assets resulting from the achievement of specific clinical...
Peer comparison
Similar to milestone-related intangible asset additions or capitalized development costs seen in other biotech licensing and collaboration arrangements.
Metric ID:
insm_segment_astrazeneca_milestone_additionsHistorical Data
5 periods
| Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|
| Value | $11.25M | $11.25M | $11.25M | $11.25M | $0.00 |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -100.0% |
| YoY Change | — | — | — | — | -100.0% |
Range$0.00 – $11.25M
CAGR-100.0%
Avg YoY Growth-100.0%
Median YoY Growth-100.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Insmed's astrazeneca milestone — additions?
- Insmed (INSM) reported astrazeneca milestone — additions of $0.00 in Q1 2026.
- How has Insmed's astrazeneca milestone — additions changed year-over-year?
- Insmed's astrazeneca milestone — additions decreased by 100.0% year-over-year, from $11.25M to $0.00.
- What does astrazeneca milestone — additions mean?
- The total value of new intangible assets recognized during the period due to milestone achievements with AstraZeneca.